Adjuvant chemotherapy after radical cystectomy:Do all patients who need chemotherapy after surgery actually receive it?
作者机构：Department of UrologyKaplan Medical CenterRehovotIsrael
出 版 物：《当代泌尿学（英文）》 (Current Urology)
年 卷 期：2023年第17卷第2期
页 面：109-112页
学科分类：0710[理学-生物学] 1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学]
主 题：Adjuvant chemotherapy Muscle-invasive bladder cancer Neoadjuvant chemotherapy
摘 要：Background:Compliance with the guideline recommendations for neoadjuvant chemotherapyin patients with muscle-invasive bladder cancer is *** adjuvant chemotherapy approach has the advantage of pathology-based decision-making,allowing for pa-tient *** addition,radical surgery is not delayed and treatment-related toxicity does not impair surgical *** proportion of patients who completed chemotherapy after cystectomy among those who were fit and in need of treatment were *** rea-sons for not completing adjuvant chemotherapy were determined. Materials and methods:We retrospectively evaluated all patients who had undergone radical cystectomy at our center over thelast 7 *** for adjuvant chemotherapy included pathological T2,any node+,or surgical margin *** patients who were fit for chemotherapy before surgery were included in the study. Results:Of the 52 patients with muscle-invasive bladder cancer,14 received neoadjuvant chemotherapy or unfit for chemotherapy were *** the remaining 38 patients,14(37％)had bladder-confined cancers and did not require additional *** the 24 patients who needed chemotherapy and were fit to receive it,8 patients completed treatment(33％),and 3 discontinued treatment due to *** patients(50％)declined chemotherapy,whereas 1 patient became unfit for chemotherapy after surgery. Conclusions:While the adjuvant chemotherapy approach could save unnecessary treatment in 37％of patients,two-thirds of those who needed chemotherapy did not complete *** refusal was the primary reason for not receiving treatment.